Vectorial-based analysis of dual-tracer PET imaging: A proof of concept

Background: The diagnosis of neurological diseases is complicated since they often share similar symptoms and occur in different severity levels. Imaging techniques such as PET molecular imaging are helpful for an early and accurate diagnosis and, staging allowing a noninvasive evaluation of the disease. The combination of two radioligands in the same patient could be valuable to achieve these diagnostic goals; nevertheless, the imaging data obtained with two radioligands is commonly interpreted independently. This novel approach to combine the PET data of two radiopharmaceuticals, separately acquired in the same subject, is to obtain new quantitative metrics. PET images of patients with Parkinson's disease (PD) and healthy controls (HC) were analyzed. Voxel-by-voxel uptake is compared by combining the imaging data. Dual-tracer PET imaging analysis was tested with [C-11]DTBZ-[C-11]Raclopride as proof of concept.Results: The new proposed metric based on a resultant vector is capable of efficiently discriminating healthy controls from PD patients (p < 0.0001) allowing the detection of slight changes in patients undergoing therapeutic approaches. Significant differences were found between HC and PD patients for the evaluated radiotracers.Conclusions: The resultant vector appears to deliver useful information that could be helpful to evaluate PD patients under treatment and to improve differential diagnoses.

Automated summary

The diagnosis of neurological diseases is complicated, but PET molecular imaging can help with early and accurate diagnosis and staging. This study proposed a novel method to combine PET data of two radiopharmaceuticals and obtain new quantitative metrics. The results showed that this method can effectively differentiate healthy controls from Parkinson's disease patients and detect slight changes in patients undergoing treatment.